Boston Scientific Relying On Primo In Wake Of NIR-On-Ranger With SOX Recall
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific expects to generate $150-175 mil. U.S. stent revenue in the fourth quarter despite the firm's Oct. 5 voluntary recall of the NIR-On-Ranger coronary stent system with the SOX securing system.